ELMD vs. IRMD, RXST, EMBC, BBNX, CBLL, NPCE, AVNS, DCTH, BFLY, and BVS
Should you be buying Electromed stock or one of its competitors? The main competitors of Electromed include Iradimed (IRMD), RxSight (RXST), Embecta (EMBC), Beta Bionics (BBNX), CeriBell (CBLL), NeuroPace (NPCE), Avanos Medical (AVNS), Delcath Systems (DCTH), Butterfly Network (BFLY), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.
Electromed vs.
Electromed (NYSE:ELMD) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Iradimed received 236 more outperform votes than Electromed when rated by MarketBeat users. However, 92.59% of users gave Electromed an outperform vote while only 65.58% of users gave Iradimed an outperform vote.
Iradimed has a net margin of 26.26% compared to Electromed's net margin of 11.34%. Iradimed's return on equity of 24.12% beat Electromed's return on equity.
Electromed currently has a consensus target price of $38.00, indicating a potential upside of 86.18%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 23.84%. Given Electromed's stronger consensus rating and higher probable upside, analysts plainly believe Electromed is more favorable than Iradimed.
In the previous week, Electromed and Electromed both had 4 articles in the media. Electromed's average media sentiment score of 1.34 beat Iradimed's score of 1.20 indicating that Electromed is being referred to more favorably in the media.
Iradimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
40.8% of Electromed shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 14.0% of Electromed shares are owned by company insiders. Comparatively, 36.8% of Iradimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Electromed has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Summary
Iradimed beats Electromed on 13 of the 18 factors compared between the two stocks.
Get Electromed News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Electromed Competitors List
Related Companies and Tools
This page (NYSE:ELMD) was last updated on 5/30/2025 by MarketBeat.com Staff
Buy ELMD Stock Free ELMD Stock Alerts